Trial Profile
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Mar 2021
Price :
$35
*
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 23 Mar 2021 Results assessing impact of kidney or hepatic impairment on somapacitan exposure in adults.in two studies (NCT03186495 & NCT03212131), published in the Clinical Pharmacokinetics.
- 01 Jun 2018 Status changed from active, no longer recruiting to completed.
- 13 Apr 2018 Planned primary completion date changed from 25 Apr 2018 to 16 May 2018.